Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
Key Highlights
- ➤Q3 net sales $35.5 million, up 30% year over year
- ➤Q3 PBP channel sales $13.6 million, up 118% year over year
- ➤Q3 net loss $24.4 million versus $14.2 million last year
- ➤2026 revenue guidance raised to approximately $124 million-$126 million
- ➤Mint FDA cleared; U.S. commercial launch expected in Q1 2027
IRVINE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2026 and updated its full year guidance for the year ending December 31, 2026.
Third Quarter 2026 Financial Highlights & Key Metrics * Net sales of $35.5 million, up 30% compared to $27.3 million in the third quarter of 2025. * Durable Medical Equipment (DME) channel net sales of $21.9 million, up 4% compared to $21.0 million in the third quarter of 2025. * Pharmacy Benefit Plan (PBP) channel net sales of $13.6 million, up 118% compared to $6.2 million in the third quarter of 2025.
Get started
Create a free account to read the full story.